PR001 (LY3884961)
Early / Mid-stage
active
active, not recruiting
CT.gov grounded
Gene-therapy Parkinson's program that gives the watchlist a cleaner exact-grounded GBA1 entry.
Program overview
- Mechanism
- GBA1 gene replacement
- Modality
- AAV gene therapy
- Phase
- Early / Mid-stage
- Status
- active
- Recruitment
- active, not recruiting
- Confidence
- medium
- Watch priority
- 2
- Last verified
- 20 Apr 2026
Sponsor and trial identifiers
- Sponsor
- Prevail Therapeutics / Eli Lilly
- Trial IDs
- NCT04127578
ClinicalTrials.gov exact matches: NCT04127578
Regions and recruitment
United States
Israel
Indication tags
Parkinson's
GBA1-associated Parkinson's
gene therapy
Milestones and catalysts
- Last milestone
- A genetically anchored Parkinson's gene-therapy program with more signal value than a duplicate legacy naming entry.
- Next expected catalyst
- Further safety and biomarker interpretation in GBA1-associated Parkinson's disease.
Related pages
Disease hub
Parkinson's disease hub
Disease-specific views with programs, mechanisms, and related context.
Related programs
Each card explains why it is here so you can read the overlap at a glance.
Mid-stage
active
active, not recruiting
A genetically targeted Parkinson's program that fits the monitor's mechanism-first framing well.
- Mechanism
- GCase pathway modulation
- Modality
- small molecule
- Next catalyst
- Further efficacy and pharmacodynamic data in GBA-associated Parkinson's disease.
- Last verified
- 20 Apr 2026
Mid-stage
active
recruiting
High-visibility Parkinson's program targeting alpha-synuclein pathology.
- Mechanism
- anti-alpha-synuclein antibody
- Modality
- monoclonal antibody
- Next catalyst
- Further progression and functional readouts.
- Last verified
- 20 Apr 2026
Mid-stage
completed
completed
Mechanism-led repurposing program that keeps the Parkinson's pipeline from being only antibody and device narratives.
- Mechanism
- glucocerebrosidase support / lysosomal modulation
- Modality
- small molecule repurposing
- Next catalyst
- Whether clinical and biomarker read-throughs justify a larger disease-modification push.
- Last verified
- 20 Apr 2026
Mid-stage
completed
completed
Parkinson's program with direct mechanistic relevance to alpha-synuclein biology rather than only symptomatic management.
- Mechanism
- alpha-synuclein misfolding inhibition
- Modality
- small molecule
- Next catalyst
- Mostly interpretive now, but still important for understanding how far small-molecule alpha-syn strategies can go.
- Last verified
- 20 Apr 2026
Recent program changes
PR001 (LY3884961)
Added to the monitor: PR001 (LY3884961) · Parkinson's disease · Early / Mid-stage.